Authors

Latest:

How to Improve Care for LGBTQI+ Patients With Cancer

As more and more people in the United States identify as lesbian, gay, bisexual, transgender, queer, intersex, or other sexual orientation or gender minority, the population of LGBTQI+ cancer survivors is becoming uniquely heterogeneous.

Claudia Aguilar Clancy, FNP-C, AOCNP

Claudia Aguilar Clancy, FNP-C, AOCNP has expertise in many areas including complete breast health care examinations and bone marrow stem cell transplantation.

Latest:

Aguilar-Clancy on the Importance of Individualized Nutritional Support as a Component of Oncology Care

Claudia Aguilar Clancy, FNP-C, AOCNP, discusses the importance of individualized nutritional support as a component of oncology care.

Patrick M. Brunner, MD

Latest:

Dr Brunner on the Role of the Dermatologist in BPDCN Diagnosis and Treatment

Patrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.

Michael W. McDermott, MD

Latest:

Test for Summarization

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

Barbara Jane O’Brien, MD

Latest:

Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast Cancer

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Bradley Monk, MD

Latest:

Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer

The panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.

David Kosoff, MD

Latest:

Immunotherapeutics Aim for Larger Role in Prostate Cancer

Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies.

Carlo Visco, MD

Carlo Visco, MD, is an associate professor of hematology in the Department of Medicine, coordinator of the Lymphoma Team in the Hematology and Bone Marrow Transplant Unit in the Section of Biomedical Innovation in the Department of Engineering for Innovative Medicine at the University of Verona

Latest:

Dr Visco on Ongoing Research to Optimize Upfront MCL Therapy

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

Douglas W. Blayney, MD, Stanford University

Latest:

Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 Trial

Douglas W. Blayney, MD, presents data from the 2021 American Society of Clinical Oncology Annual Meeting on the final results from the phase 3 PROTECTIVE-2 trial of Plinabulin and Pegfilgrastim in breast cancer patients treated with high febrile neutropenia risk chemotherapy.

Yucai Wang, MD, PhD, Mayo Clinic

Latest:

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Lena Winestone, MD

Latest:

Dr. Winestone on Disparities with Diagnosis in Pediatric Leukemia

Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.

Matthew Pierre Deek, MD

Latest:

Dr Deek on Vismodegib Plus Radiation in Locally Advanced Unresectable Basal Cell Carcinoma

Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.

Richard Lazzaro, MD, FACS

Latest:

Dr Lazzaro on Lung Cancer Screening in High-Risk Individuals

Richard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.

Greg Durm, MD

Greg Durm, MD, is an associate professor of clinical medicine in the Department of Medicine, Division of Hematology/Oncology; an associate professor of clinical otolaryngology-head & neck surgery in the Department of Otolaryngology–Head and Neck Surgery; and a full member in the Department of Experimental and Developmental Therapeutics at Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Latest:

Dr Durm on Perioperative Treatment Strategies in Early-Stage NSCLC

Greg Durm, MD, discusses factors that influence his decision to utilize perioperative treatment in patients with early-stage NSCLC.

Andrew Kuykendall, MD

Andrew Kuykendall, MD, is an assistant member in the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida.

Latest:

Dr Kuykendall on the Relevance of QOL End Points in Myelofibrosis Clinical Trials

Andrew Kuykendall, MD, discussed the advantages and limitations of using QOL- and symptom-related end points in myelofibrosis clinical research.

Tim Ho, PharmD, BCOP

Latest:

Building the Optimal Patient Experience Takes Planning and Effort

Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.

Georgia Cancer Center at Augusta University

Latest:

Cancer Researchers and Student Athletes Are “Here to Win” for Innovation, Discovery, and Hope

Building an innovative cancer research project takes time, creativity, and most importantly, a team of scientists working together on why a new way to treat cancer or keep the cancer from spreading to other parts of the body.

Nusayba Bagegni, MD

Latest:

Defining HER2-Low and -Ultralow Expression: Practical Challenges and Solutions

Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve

Dasom (Caroline) Lee, MD

Dasom (Caroline) Lee, MD, is a fellow in the Hematology and Medical Oncology Fellowship Program at Stanford Medicine, Stanford Health Care.

Latest:

Dr Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL

Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.

Ou Deng, PhD

Ou Deng, PhD, is a research scientist at Moffitt Cancer Center

Latest:

Dr Deng on the Role of MSH6 in Modulating PARP Inhibitor Sensitivity in BRCA-Proficient High-Grade Serous Ovarian Cancer

Ou Deng, PhD, discusses research aimed at clarifying the role of MSH6 in modulating sensitivity to PARP inhibitors in patients with BRCA-proficient HGSOC